Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

Allarity Therapeutics, Inc. has announced a research collaboration with the Indiana Biosciences Research Institute (IBRI) to enhance their understanding of stenoparib, a dual PARP and WNT pathway ...

A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients.

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, ...

Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers. BRCA2, a crucial player in the body's DNA repair system, aids in repairing damaged DNA.

TAMPA, Fla. — Ovarian cancer, often diagnosed at an advanced stage, presents significant treatment challenges because patients tend to develop resistance to conventional therapies quickly. Despite ...